---
document_datetime: 2025-12-02 05:13:04
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/epidyolex.html
document_name: epidyolex.html
version: success
processing_time: 0.1254654
conversion_datetime: 2025-12-28 14:15:08.528821
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Epidyolex

[RSS](/en/individual-human-medicine.xml/67234)

##### Authorised

This medicine is authorised for use in the European Union

cannabidiol Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Epidyolex](#news-on)
- [Related document](#related-document-1568)
- [More information on Epidyolex](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Epidyolex is a medicine used in addition to clobazam, to treat patients from two years of age with Lennox-Gastaut syndrome or Dravet syndrome. It is also used to treat tuberous sclerosis complex (TSC) with other epilepsy treatments in patients also aged two and above. These are rare types of epilepsy that begin in childhood and can continue into adulthood. Symptoms of these conditions include multiple types of seizure (fits), abnormal electrical activity in the brain, learning disability and behavioural problems.

The conditions are rare, and Epidyolex was designated an 'orphan medicine' (a medicine used in rare diseases). Further information on the orphan designations can be found on the European Medicines Agency's website: ( [Dravet syndrome](/en/medicines/human/orphan-designations/eu-3-14-1339) : 15 October 2014; [Lennox-Gastaut syndrome](/en/medicines/human/orphan-designations/eu-3-17-1855) : 20 March 2017; [tuberous sclerosis](/en/medicines/human/orphan-designations/eu-3-17-1959) : 17 January 2018).

Epidyolex contains the active substance cannabidiol.

Expand section

Collapse section

## How is Epidyolex used?

Epidyolex can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the treatment of epilepsy.

Epidyolex is available as a liquid containing 100 mg cannabidiol per ml. It should be taken consistently either with or without food. The recommended starting dose is 2.5 mg per kilogram body weight given twice a day. Doses are measured and given by mouth with a syringe supplied with the medicine. After one week, the dose should be increased to 5 mg/kg twice a day. Depending on the individual response and how well the medicine is tolerated, the doctor may increase the dose gradually up to a maximum of 10 mg/kg twice a day for Dravet and Lennox-Gastaut syndromes and 12.5 mg/kg twice a day for TSC. For more information about using Epidyolex, see the package leaflet or contact your doctor or pharmacist.

## How does Epidyolex work?

Although the way it works is not clearly understood, the active substance in Epidyolex, cannabidiol, is thought to act on targets that play a role in the movement of calcium in the cells. As this is important for the transmission of electrical signals in some nerve cells, and seizures are caused by excessive electrical activity in the brain, altering the movement of calcium is expected to reduce or prevent the seizures in patients with Lennox-Gastaut syndrome, Dravet syndrome or TSC. Cannabidiol is also thought to act on adenosine, a chemical messenger in the brain that plays an important role in suppressing seizures.

## What benefits of Epidyolex have been shown in studies?

Five studies in over 900 patients with Lennox-Gastaut syndrome, Dravet syndrome or TSC showed that Epidyolex lowered the number of seizures when added to treatment with other epilepsy medicines after 14 to 16 weeks of treatment.

In the first two studies, patients with Lennox-Gastaut syndrome taking Epidyolex in combination with clobazam had a reduction of up to 64% in the number of drop seizures (brief loss of muscle tone and reduced consciousness, causing abrupt falls), compared with a reduction of up to 31% for patients given placebo (a dummy treatment) with clobazam.

In another two studies in patients with Dravet syndrome, the reduction in the number of convulsive seizures (major fits with loss of consciousness) was up to 61% for patients taking Epidyolex and clobazam, and up to 38% for patients on placebo and clobazam.

In a fifth study, patients with TSC taking Epidyolex at maximum dose of 25/mg/kg/day had a reduction of 49% in the number of seizures compared with 27% in patients receiving a placebo.

## What are the risks associated with Epidyolex?

The most common side effects with Epidyolex (which may affect more than 1 in 10 people) are somnolence (sleepiness), decreased appetite, diarrhoea, fever, tiredness and vomiting. The most common reason for stopping treatment was increased blood levels of liver enzymes (a sign of liver problems). For the full list of side effects of Epidyolex, see the package leaflet.

Epidyolex must not be used in patients whose blood levels of liver enzymes are more than three times the normal limit and who also have levels of bilirubin (another marker of liver problems) more than twice the normal limit. For the full list of restrictions, see the package leaflet.

## Why is Epidyolex authorised in the EU?

The main studies showed that Epidyolex is effective at lowering the number of seizures in patients with Lennox-Gastaut syndrome, Dravet syndrome or TSC who are taking another epilepsy medicine. Regarding safety, treatment with Epidyolex is associated with an increased risk of liver problems. This risk can be managed with restrictions and regular liver monitoring and is considered acceptable given the seriousness of the conditions and the lack of treatments. The European Medicines Agency therefore decided that Epidyolex's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Epidyolex?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Epidyolex have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Epidyolex are continuously monitored. Side effects reported with Epidyolex are carefully evaluated and any necessary action taken to protect patients.

## Other information about Epidyolex

Epidyolex received a marketing authorisation valid throughout the EU on 19 September 2019.

Epidyolex : EPAR - Medicine overview

Reference Number: EMA/191061/2021

English (EN) (128.17 KB - PDF)

**First published:** 04/10/2019

**Last updated:** 26/04/2021

[View](/en/documents/overview/epidyolex-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-684)

български (BG) (145.17 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/bg/documents/overview/epidyolex-epar-medicine-overview_bg.pdf)

español (ES) (119.97 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/es/documents/overview/epidyolex-epar-medicine-overview_es.pdf)

čeština (CS) (143.64 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/cs/documents/overview/epidyolex-epar-medicine-overview_cs.pdf)

dansk (DA) (118.23 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/da/documents/overview/epidyolex-epar-medicine-overview_da.pdf)

Deutsch (DE) (122.59 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/de/documents/overview/epidyolex-epar-medicine-overview_de.pdf)

eesti keel (ET) (108.83 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/et/documents/overview/epidyolex-epar-medicine-overview_et.pdf)

ελληνικά (EL) (145.93 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/el/documents/overview/epidyolex-epar-medicine-overview_el.pdf)

français (FR) (120.63 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/fr/documents/overview/epidyolex-epar-medicine-overview_fr.pdf)

hrvatski (HR) (143.79 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/hr/documents/overview/epidyolex-epar-medicine-overview_hr.pdf)

italiano (IT) (118.95 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/it/documents/overview/epidyolex-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (152.59 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/lv/documents/overview/epidyolex-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (144.58 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/lt/documents/overview/epidyolex-epar-medicine-overview_lt.pdf)

magyar (HU) (143.25 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/hu/documents/overview/epidyolex-epar-medicine-overview_hu.pdf)

Malti (MT) (145.93 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/mt/documents/overview/epidyolex-epar-medicine-overview_mt.pdf)

Nederlands (NL) (120.01 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/nl/documents/overview/epidyolex-epar-medicine-overview_nl.pdf)

polski (PL) (144.83 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/pl/documents/overview/epidyolex-epar-medicine-overview_pl.pdf)

português (PT) (120.99 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/pt/documents/overview/epidyolex-epar-medicine-overview_pt.pdf)

română (RO) (141.42 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/ro/documents/overview/epidyolex-epar-medicine-overview_ro.pdf)

slovenčina (SK) (143.95 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/sk/documents/overview/epidyolex-epar-medicine-overview_sk.pdf)

slovenščina (SL) (140.84 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/sl/documents/overview/epidyolex-epar-medicine-overview_sl.pdf)

Suomi (FI) (117.5 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/fi/documents/overview/epidyolex-epar-medicine-overview_fi.pdf)

svenska (SV) (117.52 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

26/04/2021

[View](/sv/documents/overview/epidyolex-epar-medicine-overview_sv.pdf)

Epidyolex : EPAR - Risk-management-plan summary

English (EN) (638.71 KB - PDF)

**First published:** 04/10/2019

**Last updated:** 20/08/2024

[View](/en/documents/rmp-summary/epidyolex-epar-risk-management-plan-summary_en.pdf)

## Product information

Epidyolex : EPAR - Product Information

English (EN) (1.39 MB - PDF)

**First published:** 04/10/2019

**Last updated:** 23/05/2025

[View](/en/documents/product-information/epidyolex-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-413)

български (BG) (1.35 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/bg/documents/product-information/epidyolex-epar-product-information_bg.pdf)

español (ES) (1.31 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/es/documents/product-information/epidyolex-epar-product-information_es.pdf)

čeština (CS) (1.31 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/cs/documents/product-information/epidyolex-epar-product-information_cs.pdf)

dansk (DA) (1.29 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/da/documents/product-information/epidyolex-epar-product-information_da.pdf)

Deutsch (DE) (1.27 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/de/documents/product-information/epidyolex-epar-product-information_de.pdf)

eesti keel (ET) (1.25 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/et/documents/product-information/epidyolex-epar-product-information_et.pdf)

ελληνικά (EL) (1.31 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/el/documents/product-information/epidyolex-epar-product-information_el.pdf)

français (FR) (1.43 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/fr/documents/product-information/epidyolex-epar-product-information_fr.pdf)

hrvatski (HR) (1.38 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/hr/documents/product-information/epidyolex-epar-product-information_hr.pdf)

íslenska (IS) (1.25 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/is/documents/product-information/epidyolex-epar-product-information_is.pdf)

italiano (IT) (1.23 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/it/documents/product-information/epidyolex-epar-product-information_it.pdf)

latviešu valoda (LV) (1.32 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/lv/documents/product-information/epidyolex-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.33 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/lt/documents/product-information/epidyolex-epar-product-information_lt.pdf)

magyar (HU) (1.44 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/hu/documents/product-information/epidyolex-epar-product-information_hu.pdf)

Malti (MT) (1.45 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/mt/documents/product-information/epidyolex-epar-product-information_mt.pdf)

Nederlands (NL) (1.32 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/nl/documents/product-information/epidyolex-epar-product-information_nl.pdf)

norsk (NO) (1.22 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/no/documents/product-information/epidyolex-epar-product-information_no.pdf)

polski (PL) (1.5 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/pl/documents/product-information/epidyolex-epar-product-information_pl.pdf)

português (PT) (1.25 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/pt/documents/product-information/epidyolex-epar-product-information_pt.pdf)

română (RO) (1.28 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/ro/documents/product-information/epidyolex-epar-product-information_ro.pdf)

slovenčina (SK) (1.47 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/sk/documents/product-information/epidyolex-epar-product-information_sk.pdf)

slovenščina (SL) (1.28 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/sl/documents/product-information/epidyolex-epar-product-information_sl.pdf)

Suomi (FI) (1.23 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/fi/documents/product-information/epidyolex-epar-product-information_fi.pdf)

svenska (SV) (1.38 MB - PDF)

**First published:**

04/10/2019

**Last updated:**

23/05/2025

[View](/sv/documents/product-information/epidyolex-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000274232 22/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Epidyolex : EPAR - All authorised presentations

English (EN) (64.06 KB - PDF)

**First published:** 04/10/2019

**Last updated:** 19/06/2023

[View](/en/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-928)

български (BG) (43.23 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/bg/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.43 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/es/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_es.pdf)

čeština (CS) (38.51 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/cs/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (17.04 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/da/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.11 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/de/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (16.89 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/et/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (41.43 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/el/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_el.pdf)

français (FR) (16.61 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/fr/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (35.86 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/hr/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (17.43 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/is/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.06 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/it/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (40.58 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/lv/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (34.5 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/lt/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (40.87 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/hu/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (38.1 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/mt/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (16.34 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/nl/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (17.07 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/no/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_no.pdf)

polski (PL) (53.89 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/pl/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.13 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/pt/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_pt.pdf)

română (RO) (39.76 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/ro/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (39.69 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/sk/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (26.81 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/sl/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (16.58 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/fi/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16.95 KB - PDF)

**First published:**

04/10/2019

**Last updated:**

19/06/2023

[View](/sv/documents/all-authorised-presentations/epidyolex-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Epidyolex Active substance cannabidiol International non-proprietary name (INN) or common name cannabidiol Therapeutic area (MeSH)

- Lennox Gastaut Syndrome
- Epilepsies, Myoclonic

Anatomical therapeutic chemical (ATC) code N03AX

### Pharmacotherapeutic group

Antiepileptics

### Therapeutic indication

Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.

## Authorisation details

EMA product number EMEA/H/C/004675

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Jazz Pharmaceuticals Ireland Limited

Fifth Floor Waterloo Exchange

Opinion adopted 25/07/2019 Marketing authorisation issued 19/09/2019 Revision 18

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Epidyolex : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (245.52 KB - PDF)

**First published:** 23/05/2025

[View](/en/documents/procedural-steps-after/epidyolex-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Epidyolex : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (150.6 KB - PDF)

**First published:** 12/02/2020

**Last updated:** 23/05/2025

[View](/en/documents/procedural-steps-after/epidyolex-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Epidyolex-H-C-4675-II-0020 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/254054/2023

English (EN) (754.71 KB - PDF)

**First published:** 04/07/2023

[View](/en/documents/variation-report/epidyolex-h-c-4675-ii-0020-epar-assessment-report_en.pdf)

Epidyolex-H-C-4675-P46-009 : EPAR - Assessment Report

Adopted

Reference Number: EMA/69811/2022

English (EN) (1.06 MB - PDF)

**First published:** 04/02/2022

[View](/en/documents/variation-report/epidyolex-h-c-4675-p46-009-epar-assessment-report_en.pdf)

Epidyolex - EMEA-H-C-004675-P46-008 : EPAR - Assessment Report

Reference Number: EMA/350871/2021

English (EN) (3.98 MB - PDF)

**First published:** 23/06/2021

[View](/en/documents/variation-report/epidyolex-emea-h-c-004675-p46-008-epar-assessment-report_en.pdf)

Epidyolex : Orphan maintenance assessment report (post-authorisation)

Adopted

Reference Number: EMADOC-1700519818-654396

English (EN) (409.24 KB - PDF)

**First published:** 26/04/2021

[View](/en/documents/orphan-maintenance-report-post/epidyolex-orphan-maintenance-assessment-report-post-authorisation_en.pdf)

Epidyolex-H-C-4675-II-0005: EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/168137/2021

English (EN) (6.05 MB - PDF)

**First published:** 26/04/2021

[View](/en/documents/variation-report/epidyolex-h-c-4675-ii-0005-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Epidyolex (II-05)

Adopted

Reference Number: EMA/CHMP/51910/2021

English (EN) (122.81 KB - PDF)

**First published:** 26/02/2021

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-epidyolex-ii-05_en.pdf)

Epidyolex-H-C-4675-P46-002 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/116928/2020

English (EN) (1.26 MB - PDF)

**First published:** 26/06/2020

[View](/en/documents/variation-report/epidyolex-h-c-4675-p46-002-epar-assessment-report_en.pdf)

Epidyolex-H-C-4675-P46-005; P46-006 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/279952/2020

English (EN) (2.14 MB - PDF)

**First published:** 22/10/2013

**Last updated:** 18/09/2020

[View](/en/documents/variation-report/epidyolex-h-c-4675-p46-005-p46-006-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Epidyolex : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/428872/2019

English (EN) (375.56 KB - PDF)

**First published:** 04/10/2019

[View](/en/documents/orphan-maintenance-report/epidyolex-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Epidyolex : EPAR - Public assessment report

Adopted

Reference Number: EMA/458106/2019

English (EN) (4.84 MB - PDF)

**First published:** 04/10/2019

[View](/en/documents/assessment-report/epidyolex-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Epidyolex

Adopted

Reference Number: EMA/CHMP/417900/2019

English (EN) (103.14 KB - PDF)

**First published:** 26/07/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-epidyolex_en.pdf)

#### News on Epidyolex

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023) 26/04/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2021) 26/02/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019) 26/07/2019

#### Related document

Questions and answers on the outcome of assessment on use of Epidyolex (cannabidiol)

Adopted

Reference Number: EMA/186960/2023

English (EN) (103.82 KB - PDF)

**First published:** 28/04/2023

[View](/en/documents/medicine-qa/questions-and-answers-outcome-assessment-use-epidyolex-cannabidiol_en.pdf)

#### More information on Epidyolex

- [EU/3/14/1339 - orphan designation for treatment of Dravet syndrome](/en/medicines/human/orphan-designations/eu-3-14-1339)
- [EU/3/17/1855 - orphan designation for treatment of Lennox-Gastaut syndrome](/en/medicines/human/orphan-designations/eu-3-17-1855)
- [EMEA-001964-PIP01-16-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001964-pip01-16-m04)
- [EU/3/17/1959 - orphan designation for treatment of tuberous sclerosis](/en/medicines/human/orphan-designations/eu-3-17-1959)
- [EMEA-001964-PIP02-19 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001964-pip02-19)
- [A Prospective, Observational Cohort Study to Assess Long-Term Safety in Patients Prescribed Epidyolex® with a Focus on Drug-induced Liver Injury (DILI) - post-authorisation study](https://catalogues.ema.europa.eu/study/50740)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 23/05/2025

## Share this page

[Back to top](#main-content)